PriceTargets.com logo

ProMIS Neurosciences - PMN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 306.09%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.97 As of 04/18/2024 01:00 AM ET
▲ +0.11 (5.91%)

This chart shows the closing price for PMN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProMIS Neurosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PMN

Analyst Price Target is $8.00
▲ +306.09% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ProMIS Neurosciences in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 306.09% upside from the last price of $1.97.

This chart shows the closing price for PMN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in ProMIS Neurosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/2/2023BTIG ResearchInitiated CoverageBuy$8.00Low
7/17/2023Leede Jones GabReiterated RatingSpeculative BuyLow
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ProMIS Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $1.97
Low: $1.86
High: $2.15

50 Day Range

MA: $2.04
Low: $1.75
High: $2.49

52 Week Range

Now: $1.97
Low: $0.95
High: $8.95

Volume

13,493 shs

Average Volume

40,588 shs

Market Capitalization

$37.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of ProMIS Neurosciences?

The following Wall Street analysts have issued research reports on ProMIS Neurosciences in the last year: BTIG Research, and Leede Jones Gab.
View the latest analyst ratings for PMN.

What is the current price target for ProMIS Neurosciences?

1 Wall Street analysts have set twelve-month price targets for ProMIS Neurosciences in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 306.1%. BTIG Research has the highest price target set, predicting PMN will reach $8.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $8.00 for ProMIS Neurosciences in the next year.
View the latest price targets for PMN.

What is the current consensus analyst rating for ProMIS Neurosciences?

ProMIS Neurosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PMN will outperform the market and that investors should add to their positions of ProMIS Neurosciences.
View the latest ratings for PMN.

What other companies compete with ProMIS Neurosciences?

Other companies that are similar to ProMIS Neurosciences include Cara Therapeutics, Unicycive Therapeutics, Marker Therapeutics, BriaCell Therapeutics and Eledon Pharmaceuticals. Learn More about companies similar to ProMIS Neurosciences.

How do I contact ProMIS Neurosciences' investor relations team?

ProMIS Neurosciences' physical mailing address is 1920 Yonge Street Suite 200, Toronto A6, M4S 3E2. The company's listed phone number is (416) 847-6898 and its investor relations email address is [email protected]. The official website for ProMIS Neurosciences is www.promisneurosciences.com. Learn More about contacing ProMIS Neurosciences investor relations.